Description
The 7H11 monoclonal antibody specifically recognizes mouse CD370 which is also known as DNGR-1 (Dendritic cell natural killer lectin group receptor 1). CD370 is an ~27 kDa single-pass type II transmembrane glycoprotein that is encoded by Clec9A (C-type lectin domain family member 9A) which belongs to the C-type lectin superfamily. CD370 (Clec9a) is selectively expressed as a disulfide-linked homodimer on plasmacytoid dendritic cells and CD8+ myeloid dendritic cells. This receptor is comprised of an extracellular region that contains a C-type lectin domain with a single carbohydrate recognition domain (CRD), followed by a transmembrane segment and a cytoplasmic tail with an immunoreceptor tyrosine-based activation motif (ITAM). CD370 (Clec9a) acts as a damage-associated molecular pattern receptor, ie, an endocytic receptor for damage-associated molecular patterns (DAMPs) that are expressed by necrotic cells, eg, cells dying due to infection or transformation. This receptor binds by its extracellular domain to exposed F-actin-myosin complexes of dead cells. Intracellular signaling mediated through ligand-bound CD370 (Clec9a) leads to phosphorylation of Syk tyrosine kinase. Further downstream signaling can foster MHC Class I-mediated cross-presentation of dead-cell associated antigens by dendritic cells to CD8+ T cells.
Bead-based compensation or unmixing controls, such as BD® CompBeads or BD™ SpectraComp™, can be used as surrogates to assess fluorescence spillover when bound to fluorochrome-conjugated antibodies. Although these beads have spectral properties similar to cells, variations in spectral emission may occur, resulting in differing spillover values compared to biological controls. Therefore, it is considered best practice to compare the spillover obtained from cells and bead-based controls when using BD® CompBeads or BD™ SpectraComp™ for the first time, to ensure they are appropriate for the intended application.
The monoclonal antibody was purified from tissue culture supernatant or ascites by affinity chromatography. The antibody was conjugated to the dye under optimum conditions that minimize unconjugated dye and antibody. Store undiluted at 4°C and protected from prolonged exposure to light. Do not freeze.
1. Please refer to www.bdbiosciences.com/us/s/resources for technical protocols.
2. Please refer to http://regdocs.bd.com to access safety data sheets (SDS).
3. For U.S. patents that may apply, see bd.com/patents.
4. Caution: Sodium azide yields highly toxic hydrazoic acid under acidic conditions. Dilute azide compounds in running water before discarding to avoid accumulation of potentially explosive deposits in plumbing.
5. Since applications vary, each investigator should titrate the reagent to obtain optimal results.
6. The production process underwent stringent testing and validation to assure that it generates a high-quality conjugate with consistent performance and specific binding activity. However, verification testing has not been performed on all conjugate lots.
7. When using high concentrations of antibody, background binding of this dye to erythroid fragments produced by ammonium chloride-based lysis, such as with BD Pharm Lyse™ Lysing Buffer (Cat. No. 555899), has been observed when the antibody conjugate was present during the lysis procedure. This may cause nonspecific staining of target cells, such as leukocytes, which have bound the resulting erythroid fragments. This background can be mitigated by any of the following: titrating the antibody conjugate to a lower concentration, fixing samples with formaldehyde, or removing erythrocytes before staining (eg, gradient centrifugation or pre-lysis with wash). This background has not been observed when cells were lysed with BD FACS™ Lysing Solution (Cat. No. 349202) after staining.
8. For fluorochrome spectra and suitable instrument settings, please refer to our Multicolor Flow Cytometry web page at www.bdbiosciences.com/colors.
9. An isotype control should be used at the same concentration as the antibody of interest.
10. Please observe the following precautions: We recommend that special precautions be taken (such as wrapping vials, tubes, or racks in aluminum foil) to protect exposure of conjugated reagents, including cells stained with those reagents, to any room illumination. Absorption of visible light can significantly affect the emission spectra and quantum yield of tandem fluorochrome conjugates.
11. Alexa Fluor™ is a trademark of Life Technologies Corporation.
